Pulmozyme filed in Japan for ultra rare cystic fibrosis
This article was originally published in Scrip
Executive Summary
The Roche subsidiary Chugai has filed for the approval in Japan of Pulmozyme (dornase alfa) for the improvement of pulmonary function in cystic fibrosis (CF) patients.